Uncategorized
DME implant receives Austrian marketing OK
The Austrian Agency for Health and Food Safety has granted marketing authorization to an intravitreal
implant with sustained-release fluocinolone acetonide (Iluvien, Alimera Sciences Inc.) for the treatment of vision
impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available
therapies.